lung ultrasound to diagnose pneumonia?

A​n Italian prospective study was just published looking at the merits of ultrasound in diagnosing pneumonia (see pneumonia dx ultrasound am j em med 2015 in dropbox, or Am J Emerg Med 2015 May; 33:620.). prior studies have found that chest xray (CXR) is not so sensitive, 43.5% in one study when compared to chest CT (which is considered the gold standard).  details:

--275 patients with respiratory complaints (60% dyspnea, 25% cough, 10% purulent sputum, 15% pleuritic chest pain) and underwent chest CT. mean age 71, 53.3% women. 
--Chest CT was positive for pneumonia (PNA) in 87 patients, with "almost perfect" concordance between the readings of 2 radiologists.
--lung ultrasound (LUS), done within 3 hours of the CT, and was positive in 81 patients. 72 of them (88.9%) also had a positive chest CT
    --the 9 false positives were: 3 lung cancer nodules, 3 cases of impaired ventilation not due to PNA, 3 cases of fibrotic bands
    --the 15 false negatives were: 3 cases of posterior consolidations (the LUS was only performed on anterior-lateral chest), 5 cases of deep infection without contact with the pleura
    ​--overall sensitivity was 82.8% (73.2-90%) and specificity was 95.5% (91.5-97.9%)
    --interobserver variability: "almost perfect"
    --in subgroup of patients with pleuritic chest pain: sensitivity was 91.7% and specificity was 97.4%
    --in subgroup wihtout pleuritic chest pain: sensitivity was 81.3% and specificity was 95% (other studies found LUS less reliable with deep-seated infections)
--CXR was done in addition to LUS in 190 patients:
    ​--sensitivity of LUS was 81.4% and of CXR was 64.3% (difference significant with p=0.036); specificities were similar (94.2% vs 90%)
--so, overall, LUS rules in consolidation well (+ likelihood ratio of 18.2), and is moderately good in ruling out consolidation ( - LR=0.18)

so, pretty inmpressive. this study confirms the relatively poor showing of CXR in diagnosing PNA, and found that LUS was really quite good, and the usual ultrasound concern of intra-observer variability was minimal. although this needs to be validated in other settings, this study does hold out the promise of a noninvasive and nonradiation-associated evaluation of pneumonia.

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

cystatin c: better predictor of bad outcomes than creatinine

  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr ...
Read more

diabetes DPP-4 inhibitors and the risk of heart failure

the FDA just came out with a safety alert about 2 DPP-4 inhibitors and the increased risk of heart failure (released 04/05/2016)(see  http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery ​ ). details: --saxagliptin and alogliptin were singled out because of 2 clinical trials in diabetic patients with heart disease. in each trial more patients taking these meds were hospitalized for heart failure vs those on placebo     --in the saxagliptin trial: 3.5% were hospitalized for heart failure (vs 2.8% on placebo). risk factors included prior heart failure or kidney disease     --in the alogliptin trial: 3.9% were hospitalized for heart failure (vs 3.3% on placebo) --recommendation by the FDA:     -- we should consider stopping these drugs if the patient develops heart failure ...
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:          ...
Read more